Do 'testosterone boosting' peptides actually raise T levels?

What did @nattyplusprotocol actually say?

The creator argued that no peptide reliably boosts testosterone in a practical, sustained way. SARMs, they noted, "can mimic testosterone's androgenic effects" but suppress endogenous production. HCG works by mimicking luteinizing hormone (LH), which comes with the tradeoff of suppressing the body's own LH output over time. Kisspeptin was flagged as transient and impractical, with a half-life of roughly five minutes and a testosterone bump of "30% or so" lasting only hours. The creator ultimately landed on enclomiphene as the more viable option, even while acknowledging it's not a peptide at all, it's a SERM. The overall framing was skeptical and category-agnostic, which is a reasonable stance.

One note on terminology: the creator repeatedly says "psalm" when clearly meaning SARM (Selective Androgen Receptor Modulator). This is likely an auto-correct or speech recognition artifact, not a content error, but it's worth flagging for clarity.

Does the science back this up?

Mostly, yes. The mechanisms described for HCG and kisspeptin are biologically accurate, even if some of the specifics deserve scrutiny. The creator's skepticism about practical peptide-based testosterone optimization is well-founded given the current evidence base.

HCG acts as an LH analog at the Leydig cells in the testes, stimulating testosterone synthesis. This is well-established (Coviello et al., 2005, Journal of Clinical Endocrinology and Metabolism). The claim that prolonged HCG use can suppress endogenous LH to near-zero is supported by evidence showing negative feedback through elevated testosterone and estradiol on the hypothalamic-pituitary axis (Depenbusch et al., 2002, Human Reproduction).

Kisspeptin's role in stimulating GnRH neurons is also well-documented. A study by Jayasena et al. (2014, Journal of Clinical Investigation) confirmed that kisspeptin-54 administration increases LH and testosterone transiently in men. The five-minute half-life figure for shorter kisspeptin analogs is consistent with published pharmacokinetic data, though kisspeptin-54 has a longer half-life closer to 28 minutes (Dhillo et al., 2005, Journal of Clinical Endocrinology and Metabolism).

What did they get wrong (or right)?

The creator got the broad strokes right but glossed over some important nuances. The half-life claim for kisspeptin deserves more precision. The five-minute figure applies to kisspeptin-10, the shorter fragment, not kisspeptin-54, which has a meaningfully longer half-life and has been used in clinical research settings with intermittent dosing protocols.

The claim about HCG suppressing LH "to zero" with prolonged use is directionally correct but overstated. Studies show LH suppression, but complete and sustained suppression to zero is not universal and depends on dose, duration, and individual variation (Depenbusch et al., 2002). Saying it drops to zero implies a certainty the data doesn't fully support.

The enclomiphene comparison is interesting and not wrong, but the creator breezed past the fact that enclomiphene is a prescription drug with its own risk profile, including potential effects on lipids and vision (Kim et al., 2013, BJU International). Framing it casually as a convenient oral alternative without that context is a gap, not a fabrication, but a gap.

Credit where it's due: the creator's point that molecular categories like "peptide" are structural labels, not functional ones, is scientifically sound and a genuinely useful framing for this audience.

What should you actually know?

If you're considering any of these compounds, the honest picture is this: there is no peptide currently in widespread clinical use that sustainably and practically raises endogenous testosterone without affecting the hypothalamic-pituitary-testicular (HPT) axis in some way. That's not a failure of peptide science, it's just how the feedback loop works.

HCG is used clinically as a fertility treatment and as an adjunct in testosterone replacement therapy to preserve testicular function and size. It is not approved for general testosterone optimization, and long-term use outside medical supervision carries real risks including desensitization of LH receptors in the testes (Valenti et al., 2011, Journal of Andrology).

Kisspeptin remains largely in the research phase for male hypogonadism. Its therapeutic window and optimal dosing in men are still being studied. It is not available as an approved therapeutic in the US.

Enclomiphene is not a peptide and is not FDA-approved for testosterone optimization in men, though it has been studied for that purpose. Any use outside approved indications should involve a licensed clinician who can monitor labs and assess individual risk.

The creator's bottom line, that you should evaluate compounds individually rather than by category, is pragmatic and reflects how endocrinologists actually think about this space.